# XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

Study · id `cardio:ct-nct01178268` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01178268](<https://clinicaltrials.gov/study/NCT01178268>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01178268

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 546 participants.

## Technical summary

Registry record NCT01178268. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2016-08-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 546 participants (enrolled count; ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Primary completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Results first posted: 2016-08-24 (ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01178268, source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01178268-2016-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
- Condition: Coronary Occlusion
- Condition: Thrombosis (Stent Thrombosis)
- Condition: Vascular Disease
- Condition: Myocardial Ischemia
- Condition: Coronary Artery Stenosis
- Condition: Coronary Disease
- Condition: Coronary Artery Disease
- Condition: Coronary Restenosis
- Intervention (Device): XIENCE V EECSS
- Intervention (Device): CYPHER SELECT PLUS SECSS
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 85135a23669b2b5275f281675ec11bd6ed5b3d6418e7a234ec62d875446bdff5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
